Patents by Inventor Kyle Edgar

Kyle Edgar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Copolymer compatibilizers and uses thereof
    Patent number: 12091484
    Abstract: Described herein are block copolymers that can be used as compatibilizers. The block copolymers can be graft block or triblock copolymers. The block copolymers can include a polysaccharide or a polyester and a polyolefin. Also described herein are polymer blends that can include and be made using the block copolymers described herein.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: September 17, 2024
    Assignee: Virginia Tech Intellectual Properties, Inc.
    Inventors: John Matson, Kyle Arrington, Kevin Edgar, Junyi Chen
  • METHODS OF TREATMENT WITH TASELISIB
    Publication number: 20160375033
    Abstract: Taselisib (GDC-0032) induces the degradation of mutant-p110 alpha protein. Methods for selecting patients with mutant PI3K tumors for treatment with taselisib are described.
    Type: Application
    Filed: June 28, 2016
    Publication date: December 29, 2016
    Applicant: Genentech, Inc.
    Inventors: Kyle Edgar, Lori Friedman, Deepak Sampath, Kyung Song, Ingrid Wertz, Timothy Wilson
  • VIPR1S as Modifiers of the E2F/RB Pathway and Methods of Use
    Publication number: 20100112566
    Abstract: Human VIPR1 genes are identified as modulators of the E2F/RB pathway, and thus are therapeutic targets for disorders associated with defective E2F/RB function. Methods for identifying modulators of E2F/RB, comprising screening for agents that modulate the activity of VIPR1 are provided.
    Type: Application
    Filed: September 24, 2007
    Publication date: May 6, 2010
    Inventors: Kyle A. Edgar, Kimberly Carr Ferguson, Monique Nicoll, Christopher G. Winter
  • Facls as modifiers of the rb pathway and methods of use
    Publication number: 20060240433
    Abstract: Human FACL genes are identified as modulators of the RB pathway, and thus are therapeutic targets for disorders associated with defective RB function. Methods for identifying modulators of RB, comprising screening for agents that modulate the activity of FACL are provided.
    Type: Application
    Filed: January 28, 2004
    Publication date: October 26, 2006
    Inventors: Helen Francis-Lang, Kyle Edgar, Kim Lickteig